AbbVie or Altria: The One Dividend Stock I’d Hold for the Next 10 Years
AbbVie (ABBV) lowered its 2026 adjusted EPS guidance to $13.76-$13.96 due to $1.25B in expenses. Altria (MO) offers a 6.2% yield vs. AbbVie's 2.6%. AbbVie's dividend growth is faster but uses more free cash flow. Altria's EPS growth outlook is 3.5%-5.5% for 2026. Both companies face different growth and dividend sustainability challenges.
How this was made
The 30-second read
Why it matters
For ABBV, the combination of a guidance cut, rising payout ratio, and shrinking free-cash-flow cushion increases perceived dividend risk and may weigh on valuation. For MO, the higher yield and narrower growth outlook range are positioned as a more defensive alternative, though the piece is largely comparative rather than a fresh MO catalyst.
Market read
Dividend investors may reassess ABBV’s cash-return durability after the guidance cut and worsening payout metrics, while MO may attract relative inflows due to higher yield framing.
What to watch
The article does not quantify how much of the free-cash-flow decline is temporary versus structural, nor does it detail Apogee deal timing and integration effects on leverage and future cash generation.
Background
The article compares AbbVie’s and Altria’s dividend durability, focusing on AbbVie’s Oct. 5 2026 EPS guidance reduction and cash-flow-to-dividend coverage trends versus Altria’s higher yield and steadier outlook framing.
Ticker impact
AbbVie lowered 2026 adjusted EPS guidance to $13.76 to $13.96, citing $1.25B of acquired IPR&D and milestone expenses.
Likely downward pressure as investors reprice 2026 earnings and the sustainability of the dividend payout ratio.
The article ties the EPS guide reduction to specific expenses and highlights a rising payout ratio and shrinking free-cash-flow cushion, which are direct valuation and risk inputs for dividend investors.
Altria is contrasted as offering a higher yield and narrower 2026 outlook growth range of 3.5% to 5.5% adjusted EPS growth.
Likely relative outperformance versus ABBV as dividend-focused investors rotate toward the higher yield and steadier payout framing.
The article provides limited MO-specific new disclosures beyond the stated outlook range and yield comparison, so directional impact is more relative than absolute.
Market effects
Reinforces a dividend-and-cash-flow risk lens for large-cap pharma and tobacco, with pipeline spend and payout ratios driving relative valuation.
Primarily US dividend equity positioning, with rotation between defensive yield names.
Limited, as the catalysts are company-specific guidance and dividend coverage metrics.
Counterpoint
AbbVie’s guidance cut is tied to identifiable pipeline acquisition costs, and strong growth in Skyrizi and Rinvoq could offset near-term payout ratio pressure.
Key entities
- companyAbbVie
Lowered 2026 adjusted EPS guidance to $13.76 to $13.96 and highlighted dividend coverage pressure via rising payout ratio.
- companyAltria Group
Framed as higher-yield alternative with 2026 adjusted EPS growth outlook of 3.5% to 5.5%.
- productSkyrizi
AbbVie drug cited as growing more than 20% in Q2 2026.
- productRinvoq
AbbVie drug cited as growing more than 20% in Q2 2026.
- corporate eventApogee acquisition
AbbVie planned acquisition referenced in relation to net leverage targets and pipeline spend.
